Agenzia Italiana del Farmaco
Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017 - Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017
Updated lists of allergens for specific immunotherapy and diagnosis published following the end of the transitional phase initiated with AIFA Decision DG 2130/2017
Following the withdrawal of some registration procedures on a voluntary basis by the companies concerned, the lists already published following the conclusion of the transitional phase started with AIFA Decision DG 2130/2017 were updated on 2st February 2023.
Specifically, the update concerns the lists of allergens for specific immunotherapy and diagnosis for which companies may continue the procedure for obtaining a marketing authorisation (Annex 1), for which the Agency has issued a refusal to continue the procedure (Annex 2) and for which companies have waived the procedure for obtaining a marketing authorisation (Annex 3).
Published on: 02 February 2023
Il CdA #AIFA ha audito le principali società scientifiche di neurologia e le associazioni dei pazien...
Vai al post →
📢 Il CdA #AIFA approva la rimborsabilità di 4 nuovi #farmaci, 9 estensioni di indicazioni terapeuti...
Vai al post →
📢 #AIFA comunica il calendario degli incontri nell’ambito delle iniziative dedicate al dialogo e al...
Vai al post →
🔬 AIFA pubblica il dossier “Dalle terapie a taglia unica alle cure su misura: la rivoluzione della ...
Vai al post →
🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m...
Vai al post →
💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ...
Vai al post →
